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Abstract
Nuclear factor (NF)-κB signalling is required for lung adenocarcinoma development in mice,
and both of its subunits RelA and RelB were independently reported to be highly expressed
in human non-small cell lung cancer (NSCLC). To comprehensively examine NF-κB expres-
sion in NSCLC, we analyzed serial sections of primary tumor samples from 77 well-docu-
mented patients (36 adenocarcinomas, 40 squamous cell carcinomas and 3 large cell
carcinomas) for immunoreactivity of RelA, RelB, P50, and P52/P100. Tumor and intratu-
moral stroma areas were discriminated based on proliferating cell nuclear antigen immuno-
reactivity and inflammatory infiltration was assessed in intratumoral stroma areas. NF-κB
immunoreactivity was quantified by intensity, extent, and nuclear localization and was
cross-examined with tumor cell proliferation, inflammatory infiltration, and clinical-pathologic
data. We found that the expression of the different NF-κB subunits was not concordant, war-
ranting our integral approach. Overall, RelA, RelB, and P50 were expressed at higher levels
compared with P52/P100. However, RelA and P50 were predominantly expressed in intra-
tumoral stroma, but RelB in tumor cells. Importantly, tumor area RelA expression was corre-
lated with the intensity of inflammatory infiltration, whereas RelB expression was identified
in proliferating tumor cells. Using multiple logistic regression, we identified that tumor RelB
expression was an independent predictor of lymph node metastasis, and tumor P50 was an
independent predictor of TNM6 stage IIB or higher, whereas tumor RelA was an indepen-
dent predictor of inflammatory infiltration. We conclude that pathologic studies of NF-κB
expression in cancer should include multiple pathway components. Utilizing such an
approach, we identified intriguing associations between distinct NF-κB subunits and clinical
and pathologic features of NSCLC.
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Introduction
Lung cancer is one of the most common human cancers and the leading cancer killer world-
wide [1]. Lung cancer consists of two main histologic types, small-cell lung carcinoma and
non-small-cell lung carcinoma (NSCLC), with the latter accounting for more than 80% of new
cases [2]. NSCLC represents a histologically diverse group of tumors that are subclassified into
adenocarcinomas, squamous cell carcinomas, and large cell carcinomas, accounting for 40, 30,
and 10% of new NSCLC cases, respectively [2]. Adenocarcinoma is the predominant NSCLC
subtype with rising incidence [3].
The mammalian nuclear factor (NF)-κB pathway is comprised mainly of RelA, c-Rel, RelB,
NF-κB1 (P105/P50), and NF-κB2 (P100/P52) [4]. These ubiquitous proteins form homo- or
heterodimers that reside in the cytoplasm in an inactive form, bound to inhibitory proteins
known as inhibitors of NF-κB (ΙκΒ). Upon stimulation, IκB undergo phosphorylation by
multiple IκB kinases (IKK; α, β, γ, ε, and others), as well as ubiquitination and proteolytic deg-
radation by the proteasome and other proteases, to release active NF-κB subunits for nuclear
translocation and activation of target gene transcription [5, 6]. There are two main NF-κB acti-
vation pathways, the canonical (or classical) and non-canonical (or alternative), which are
mediated by RelA/P50 or c-Rel/P50 and RelB/P52 dimers, respectively [4–7]. More recently,
additional mechanisms of NF-κB activation were unveiled, including but not limited to induc-
ible processing of P100 to P52 regulated by IKKα homodimers, further increasing the complex-
ity of the system [8]. Canonical and/or alternative NF-κB activation occurs after cellular
stimulation by cytokines, bacteria or viruses, endotoxins, oxidative stress, irradiation, etc, and
can lead to cell differentiation, proliferation, inhibition of apoptosis, and/or inflammatory sig-
nalling [9].
NF-κB activation has been identified in several human cancers, including but not limited to
lymphoma, colorectal tumors, esophageal and head and neck carcinoma, breast tumors, hepa-
tocellular carcinoma, and prostate cancer [10–16]. However, studies have focused almost
exclusively on the canonical NF-κB pathway, while the role of alternative NF-κB signalling in
tumor promotion and progression remains obscure [17–19]. In human NSCLC, increasing
nuclear RelA immunoreactivity has been described with progressive disease [20]. Canonical
NF-κB signalling has also been found to be paramount for lung tumor formation in mouse
models of NSCLC induced by oncogenic KRASG12D and/or loss of the tumor suppressors
Trp53 and Gprc5a, cigarette smoke exposure, and the tobacco carcinogen urethane [21–25].
However, other studies suggest that constitutive or tumor microenvironment-induced NF-κB
activation in NSCLC is more complex and rests on more than one pathway [26–28].
Here we set out to test this using comprehensive analyses of multiple NF-κB subunit expres-
sion of 77 well-documented patients with NSCLC. For this purpose, we developed a semi-
quantitative NF-κB subunit scoring system that takes into account both expression levels as
well as nuclear localization. We consistently identified distinct NF-κB subunit expression pat-
terns in tumor cells versus intratumoral stroma and found interesting relationships between
these patterns and clinical-pathologic features of human NSCLC. Finally, we recapitulated
some of these findings in two different mouse models of NSCLC, indicating that divergent NF-
κB activation patterns are indeed at play in NSCLC and may have different functions.
Materials and Methods
Patients
Seventy seven archival formalin-fixed, paraffin-embedded diagnostic tissue samples of patients
with NSCLC that underwent surgical resection with curative intent between 2001 and 2008 at
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the University Hospital of Patras were retrospectively enrolled in the study. Some of these
patients had also been studied in a previous report from our Institution [28]. Patients, all Cau-
casian, 69 men and 8 women aged from 46 to 84 years, were carefully selected based on the
availability of full clinical and pathologic data extracted from the primary pathology reports
and patients’ files, including age, sex, histologic type, grade, and detailed pathologic stage.
Patients selected included 34 patients with lung adenocarcinomas, 40 with squamous cell carci-
nomas, and three with large cell carcinomas. All patients were staged according to the sixth edi-
tion of the TNM classification for NSCLC, current at the time of their diagnosis [29]. The
study’s observational protocol was conducted according to the Declaration of Helsinki, was
approved by the Ethics Committee of the University Hospital of Patras, Greece, and all patients
gave written informed consent.
Mice
Experiments were approved a priori by the Veterinary Administration of Western Greece (Pro-
tocol Number: 276134/14873/2) and were conducted according to Directive 2010/63/EU
(http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=OJ:L:2010:276:0033:0079:EN:PDF).
For mutant KRAS-driven lung tumorigenesis, C57BL/6 mice heterozygous for the loxP-STOP-
loxP.KRASG12D transgene were used, which express mutant KRAS in any somatic cell upon
CRE-mediated recombination (hereafter referred to as Lskmice; Jackson Laboratories, Bar
Harbor, MN) [22]. For lung tumor induction, Lskmice received recombinant adenoviral vec-
tors encoding CRE recombinase (Ad-Cre; Baylor College of Medicine, Cell and Gene Therapy
Center, Vector Development Lab, Houston, TX) intratracheally (5x108 plaque-forming units
in 50 μl phosphate-buffered saline) and were sacrificed after four months [30]. For chemical-
induced lung tumorigenesis, FVBmice (Jackson Laboratories, Bar Harbor, MN) received the
tobacco carcinogen urethane intraperitoneally (1g/Kg in 100 μl phosphate-buffered saline) and
were sacrificed after 6 months [21, 31]. Mouse lungs were exsanguinated by 20 ml intracardiac
saline infusion, were inflated with 10% neutral-buffered formalin using 20 cmH2O pressure,
were fixed in % neutral-buffered formalin, and were embedded in paraffin.
Immunohistochemistry
Human and mouse tissue blocks were cut into 4 μm-thick sections, which were subsequently
deparaffinised by ethanol gradient, rehydrated, and boiled in heat-induced epitope antigen
retrieval solution (0.1 M sodium citrate; pH = 6.0). Endogenous peroxidase activity was inhib-
ited using 3% H2O2 and non-specific antibody-protein binding was prevented using 3%
bovine-serum albumin-containing Tris-buffered saline. The following primary antibodies and
dilutions were used overnight at 4°C: anti-P50 (sc-114 rabbit polyclonal IgG; 1/150; Santa Cruz
Biotechnology, Santa Cruz, CA), anti P100/P52 (ab31409 rabbit polyclonal IgG; 1/150; Abcam,
Cambridge, UK), anti-RelA (sc-8008 mouse monoclonal IgG; 1/200; Santa Cruz), anti-RelB
(sc-226 rabbit polyclonal IgG; 1/400; Santa Cruz), and anti-proliferating cell nuclear antigen
(PCNA; ab2426 rabbit polyclonal IgG; 1/2000; Abcam). Detection of primary antibodies was
performed using a horse radish peroxidase-conjugated polymer according to the manufactur-
er’s instructions (EnVision; Dako, Glostrup, Denmark) and diaminobenzidine as the chromo-
genic substrate. Sections were counterstained with Harris’s hematoxylin, dehydrated, and then
mounted. For isotype controls, the primary antibody was omitted. Normal tonsil tissue was
employed as positive control. All antibodies were validated for immunohistochemistry using
serial dilutions starting from 1/100 (except from PCNA where dilutions started at 1/1000) and
different bovine serum albumin concentrations in Tris–buffered saline following or modifying
the manufacturer’s instructions in order to maximize the signal to background ratio.
NF-κΒ in NSCLC
PLOSONE | DOI:10.1371/journal.pone.0132527 July 6, 2015 3 / 17
Immunoreactivity was scored by three blinded to the case investigators (I.G., H.P., and G.T.S.)
including one Hellenic board-certified pathologist (H.P.) and consensus was sought in ambigu-
ous cases by co-observation. PCNA immunoreactivity was defined as the percentage of positive
cells in tumor areas and was used to discriminate these (high percentage of immunoreactive
cells) from intra-tumoral stroma areas (low percentage of immunoreactive cells). Sections were
counted at high power (X400), and 5–8 fields were assessed randomly for tumor cells and for
intratumoral stroma areas, respectively. One thousand cell nuclei were counted respectively,
and the number of cells showing positive nuclear staining was recorded. NF-κΒ subunit
immunoreactivity was scored as follows: the intensity (0: negative; 1: weak; 2: moderate; and 3:
strong), extent (0:<10% of cells positive; 1: 10–35% of cells positive; 2: 35–70% of cells positive;
and 3:>70% of cells positive), and distribution (0: negative; 1: cytoplasmic only; 2: cytoplasmic
and nuclear; and 3: nuclear only) of immunoreactivity were scored separately for each NF-κΒ
subunit for the sample overall, as well as separately for tumor cells and intratumoral stroma of
each tumor, and were combined into subunit-specific overall, tumor, and stroma scores using
the formula: NF-κΒ subunit score = (intensity + extent)  distribution. NF-κΒ subunit scores
were further categorized into low (0–4), intermediate (5–6), and high (7–18). Inflammatory
infiltrates were determined semi-quantitatively using PCNA-stained and isotype control sam-
ples and was defined as low (<5%), moderate (5–20%), and high (>20%) depending on the
percentage of leukocytes in intratumoral stroma areas. The latter were identified by morphol-
ogy and lack of immunoreactivity for PCNA. Images were taken using an upright Axio Lab.A1
microscope connected to an AxioCam ERc 5s camera (Zeiss, Jena, Germany). For immunoflu-
orescence, tissue sections were incubated simultaneously with anti-PCNA (either ab2426 rabbit
polyclonal IgG; 1/100 dilution; Abcam for collocalization with RelA or sc-56 mouse monclonal
IgG; 1/100 dilution; Santa Cruz for collocalization with RelB) and either anti-RelA (sc-8008
mouse monoclonal IgG; 1/100 dilution; Santa Cruz) or anti-RelB (sc-226 rabbit polyclonal IgG;
1/100 dilution; Santa Cruz) antibodies as above, followed by nuclear counterstaining with
Hoechst 33258 (Molecular Probes, Eugene, OR). Detection of primary antibodies was per-
formed using donkey anti-rabbit Alexa568-conjugated (A10042; 1/500 dilution; Invitrogen,
Carlsbad, CA) and donkey anti-mouse Alexa488-conjugated (A21202; 1/500 dilution; Invitro-
gen, Carlsbad, CA) secondary antibodies. For isotype controls, either or both primary antibod-
ies were omitted. Immunoreactivity was captured on a Zeiss Axio Observer.D1 inverted
microscope connected to an AxioCamMRc 5 camera (Zeiss, Jena, Germany) and was co-regis-
tered using Fiji academic imaging freeware (http://fiji.sc/Fiji).
Statistics
Probability values (P) less than 0.05 were considered significant. Human NF-κΒ subunit scores
were not normally distributed, as tested by the Kolmogorov-Smirnov test (P< 0.05), and are
shown in bar graphs as median with boxes indicating interquartile range and whiskers indicat-
ing 95% percentiles. Matched numerical NF-κΒ subunit scores of the same tumors were com-
pared using Friedman’s tests followed by Dunn’s post-tests. Categorical NF-κΒ subunit scores
were compared using χ2 tests followed by Fisher’s exact tests. Correlations between numerical
NF-κΒ subunit scores and clinical-pathologic data were done using Spearman’s tests, whereby
the overall threshold of statistical significance (P< 0.05) was adjusted to the total number of
correlations examined (n = 153) by the Bonferroni method to P< 0.05/153 = 0.000327. Com-
parisons of numerical NF-κΒ subunit scores by inflammatory infiltration degree and clinical-
pathologic categories were done using Wilcoxon signed rank tests or Kruskal-Wallis tests
followed by Dunn’s post-tests, for two or multiple comparison groups, respectively. To deter-
mine whether numerical NF-κΒ subunit scores independently predict clinical-pathologic
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variables, the latter were dichotomized by their median and binary logistic regression analyses
were performed using the backward Waldman method. For this, NF-κΒ subunit scores were
used as the input (independent variables) and clinical-pathologic variables and inflammatory
infiltration scores as the output (dependent variables). Mouse NF-κΒ subunit scores at progres-
sive stages of carcinogenesis are presented as mean ± SD and were compared using two-way
ANOVA followed by Bonferroni post-tests. Statistical analyses were performed using Prism
v5.0.0 (GraphPad, San Diego, CA) and the Statistical Package for the Social Sciences v20 (IBM
SPSS Statistics, Chicago, IL, USA).
Results
NF-κΒ subunit expression patterns in NSCLC
The clinical and pathologic features of the study patients are summarized in Table 1. The raw
study results are appended to this article as S1 Table. We first examined NF-κΒ subunit expres-
sion in normal lung areas adjacent to our surgically resected tumor samples. In bronchial and
alveolar epithelium, RelA, P50 and P100/P52 exhibited low or moderate cytoplasmic immuno-
reactivity, while RelB displayed higher expression levels. In juxta-tumoral bronchial and
alveolar hyperplasias, immunoreactivity for all NF-κB subunits showed a stronger expression
pattern, with RelB showing both cytoplasmic and nuclear localization. In tumors, all NF-κB
subunits were highly expressed relative to normal and hyperplastic areas, with RelB scoring
highest and showing the highest degree of nuclear localization. However, RelA, RelB, and P50
immunoreactivity was stronger compared with P100/P52 (Fig 1A and 1B). When NF-κB sub-
unit scores were subdivided into low (0–4), intermediate (5–6), or high (7–18), no relationship
was evident between the different subunits (Fig 1C). No statistically significant differences
were noted between the different NSCLC histologic subtypes. However, statistically significant
differences were observed in NF-κB subunit expression levels within each tumor: tumor areas
displayed different expression patterns compared with intratumoral stroma areas (Fig 1A; rep-
resentative panels in red frame). These results suggested that multiple NF-κΒ subunits are pro-
gressively overexpressed in NSCLC, showed that not all NF-κΒ subunits are expressed equally,
Table 1. Clinical-pathologic features of 77 patients with NSCLC.
adenocarcinoma squamous cell carcinoma large cell carcinoma
Sex (male/female; n) 29/5 37/3 2/1
Age (years; range) 46–84 48–81 47–54
Differentiation (n)
None 0 0 2
Low 9 8 1
Low-intermediate 9 10 0
Intermediate 12 19 0
intermediate-high 2 2 0
High 2 1 0
pathological TNM6 stage (n)
IA 3 3 0
IB 5 9 2
IIA 10 13 0
IIB 7 5 1
IIIA 8 10 0
IIIB 1 0 0
doi:10.1371/journal.pone.0132527.t001
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Fig 1. Immunohistochemical detection of NF-κB subunits in NSCLC, juxta-tumoral normal lung structures and preneoplastic lesions. (A)
Representative images. Images in red frames representatively display differential NF-κB subunit expression in tumor and intratumoral stroma areas. (B)
NF-κΒ in NSCLC
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and identified a discordance in the expression of multiple NF-κΒ subunits between tumor and
intratumoral stromal areas, warranting further investigation.
Differential NF-κΒ expression in tumor and stromal compartments of
NSCLC
To study this in more detail, all samples were stained for PCNA, which clearly identified tumor
areas (high abundance of PCNA+ cells) from the intratumoral stroma compartment (very low
abundance of PCNA+ cells), and NF-κB subunit scoring was repeated separately for these two
areas in serial sections of all patients (Fig 2A). These analyses revealed that RelB was the sub-
unit expressed the strongest in areas of tumor cells displaying a both nuclear and cytoplasmic
expression pattern. On the other hand, the remaining subunits studied showed only moderate
cytoplasmic expression in tumor areas (Fig 2A and 2B). When tumor compartment NF-κB
subunit scores were subdivided into low (0–4), intermediate (5–6), or high (7–18) and com-
pared within each tumor, RelB and P50 showed significant discordance, with tumors with
strong RelB immunoreactivity exhibiting low P50 scores (Fig 2C). Surprisingly, evaluation
exclusively of the intratumoral stroma yielded different results: here, RelA and P50 subunits
were most predominantly expressed in the nuclei of stromal cells. In stark contrast, RelB and
P100/P52 showed only weak cytoplasmic immunoreactivity (Fig 2A and 2D). When stroma
NF-κB subunit scores were subdivided into low (0–4), intermediate (5–6), or high (7–18) and
compared within each tumor, RelB and P100/P52 showed significant concordance, with 49/77
tumors displaying simultaneously low scores for both subunits, likely reflecting the low expres-
sion levels of both proteins (Fig 2E). We finally examined the relationships between numerical
and categorical tumor and stroma scores for each NF-κB subunit, finding that only P100/P52
expression in tumor and the related stroma were concordant and correlated (Fig 2F and 2G).
Correlation of Rel subunit expression with cellular proliferation and
inflammatory infiltration
Since NF-κB is mechanistically implicated in the proliferation and inflammatory signalling of
lung tumor cells in mouse models [21–24], we sought to determine the degree of cellular prolif-
eration and inflammatory infiltration in our 77 patients with NSCLC. For this, serial sections
were subjected to PCNA immunostaining as above, with simultaneous hematoxylin staining of
isotype control sections, and the percentage of PCNA-positive cells in tumor areas was assessed
as a measure of cellular proliferation rate. In addition, the percentage of tumor-infiltrating
PCNA-negative inflammatory cells in stroma areas was determined for each patient (Fig 3A).
These analyses identified that, although expression levels of RelA in tumor areas were quite
low, they were increased in tumors with high levels of inflammatory infiltration (Fig 3B).
Moreover, although the percentage of PCNA-positive cells was not different between the differ-
ent histologic subtypes (Fig 3C), and was not associated with the expression of any NF-κB sub-
unit (data not shown), dual immunofluorescence for RelA or RelB combined with PCNA
revealed that PCNA+ proliferating cells predominantly expressed RelB in their nucleus (Fig
3D). These data indicated that tumor RelA expression was associated with inflammatory infil-
tration and that tumor RelB expression was linked with cellular proliferation within each
tumor. Since RelB expression has been found to be regulated by both the canonical as well as
Overall scoring of NF-κB subunit expression levels. Data presented as median with boxes indicating interquartile range and whiskers indicating 95%
percentiles. ns, * and ***: P > 0.05, P < 0.05, and P < 0.001 for indicated comparisons by Friedman’s test followed by Dunn’s post-tests. (C) Co-expression
matrixes of categorical NF-κB subunit expression levels. For this, NF-κB scores from (B) were categorized into low (0–4), intermediate (5–6), and high (7–
18). ns: P > 0.05 by χ2 tests followed by Fisher’s exact tests.
doi:10.1371/journal.pone.0132527.g001
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the alternative NF-κB pathways, we next sought to examine a possible correlation between
RelA expression in tumor or stroma compartments, and RelB expression in tumor cells.
Fig 2. NF-κB subunit expression patterns in tumor versus intratumoral stroma areas. (A) Representative images. (B, D) Scoring of NF-κB subunit
expression levels in tumor (B) and stroma (D) areas. Data presented as median with boxes indicating interquartile range and whiskers indicating 95%
percentiles. ns and ***: P > 0.05 and P < 0.001 for indicated comparisons by Friedman’s test followed by Dunn’s post-tests. (C, E) Co-expression matrixes of
categorical NF-κB subunit expression levels in tumor (C) and stroma (E) areas. For this, NF-κB scores from (B) and (D) were categorized into low (0–4),
intermediate (5–6), and high (7–18). ns: P > 0.05 and P: probability values by χ2 tests followed by Fisher’s exact tests. (F) Co-expression matrixes of tumor
versus stroma NF-κB subunit expression. ns: P > 0.05 and P: probability values by χ2 tests followed by Fisher’s exact tests. (G) Correlation of tumor and
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Fig 3. Association of NF-κB subunit expression with tumor-related inflammation and cellular proliferation in NSCLC. (A) Representative images of
hematoxylin-stained samples showing different degrees of inflammatory infiltration of stroma areas. (B) NF-κB subunit expression scores of tumors with
varying degrees of inflammatory infiltration. Data presented as median with boxes indicating interquartile range and whiskers indicating 95% percentiles. ns,
**, and ***: P > 0.05, P < 0.01, and P < 0.001 for indicated comparisons by Kruskal-Wallis tests followed by Dunn’s post-tests. (C) Representative images of
PCNA-stained NSCLC subtype samples. (D) Nuclear co-localization of PCNA immunoreactivity with RelB (arrows), but not with RelA, was identified using
dual immunostaining of samples of 10 patients (representative images shown).
doi:10.1371/journal.pone.0132527.g003
NF-κΒ in NSCLC
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However, no statistically significant correlation was found when the data were assessed either
in a parametric or a non-parametric fashion, suggesting that tumor RelA and RelB expression
occur independently in NSCLC.
Association of NF-κΒ subunit expression with clinical and pathologic
features of NSCLC
We next examined whether NF-κB subunit expression in tumor and stroma compartments is
correlated with clinical and pathologic features of our patients with NSCLC. For this, correla-
tion analyses were done, which revealed no significant associations (data not shown). NF-κB
scores were further subdivided according to clinical and pathologic features and subgroups
were compared (Fig 4A). The stroma score of P100/P52 was significantly lower in well-differ-
entiated tumors, as compared with low or moderately differentiated ones. In addition, stromal
P100/P52 expression was decreased in patients with N2 disease, as compared with patients
without lymphatic involvement. No other significant differences were identified regarding the
intratumoral stromal expression of any other subunit. When tumor area NF-κB scores were
examined this way, RelA was found to be expressed at higher levels in men compared with
women, in patients aged 65 and over compared with younger ones, and in patients with squa-
mous cell carcinoma compared with adenocarcinoma. Importantly, tumor P50 scores were
elevated in patients with N2 and pTNM6 stage III disease compared with patients without lym-
phatic involvement and stage II disease, respectively. Finally, tumor P100/P52 expression was
statistically significantly increased in patients with pTNM6 stage II disease compared with
patients with stage I disease. In a third level of investigations, clinical and pathologic NSCLC
features were dichotomized by their median and were entered as dependents into binary logis-
tic regression analyses, using tumor and stromal NF-κB scores as the input (independent) vari-
ables (Fig 4B). These analyses revealed that tumor RelA score was an independent predictor of
age 65 or older, of squamous histology, and of inflammatory infiltration. Interestingly, tumor
and stroma RelB expression were identified as positive and negative predictors of nodal
involvement, respectively. Finally, tumor P50 score was found to be a independent predictor of
poor differentiation and pTNM6 stage IIB or higher. Hence distinct NF-κB subunit (RelB and
P50, but not RelA) expression was associated with advanced disease, and distinct NF-κB sub-
units were linked with defined features of NSCLC, validating our integrated approach.
NF-κΒ subunit expression in mouse models of NSCLC
We finally sought to verify whether our findings could also be recapitulated in two different
mouse models of human NSCLC, namely the model of urethane-induced pulmonary adenoma
and of mutant KRAS-induced pulmonary adenocarcinoma. Analyses, done as for human sam-
ples, identified that RelB was overexpressed in urethane-induced hyperplastic lesions, but not
in adenomas. Moreover, RelB was overexpressed in both mutant KRAS-induced hyperplastic
lesions and adenocarcinomas (Fig 5). These findings were consistent with the human data
showing focal overexpression of RelB in tumor areas of human NSCLC (Fig 2).
Discussion
In the present study, we characterized the expression and the subcellular localization of several
NF-κB subunits in human NSCLC and experimental models of the disease. We found different
patterns of immunoreactivity for each of the subunits studied, justifying our integrated
approach. In specific, RelB was highly expressed in tumor cells, while RelA and P50 in stromal
cells. Interestingly, tumor RelA expression was correlated with inflammatory infiltration and
tumor RelB expression was collocalized with proliferating tumor cell nuclei. These results were
NF-κΒ in NSCLC
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consistent with binary logistic regression analyses that revealed that tumor RelA expression
was an independent predictor of inflammatory infiltrates, while tumor RelB immunoreactivity
predicted more advanced disease with nodal involvement. Finally, this pattern of predominant
RelB expression in human NSCLC was recapitulated in mouse models of the disease. Collec-
tively, our results indicate a multi-modal activation of NF-κB in NSCLC and possibly suggest
divergent functions for RelA and RelB in driving paracrine induction of inflammation and cell-
autonomous or autocrine promotion of cellular proliferation, respectively (Fig 6).
Fig 4. Association of NF-κB expression with clinical and pathologic parameters in 77 patients with NSCLC. (A) NF-κB expression levels subdivided
by clinical and pathological parameters. Data presented as median with boxes indicating interquartile range and whiskers indicating 95% percentiles. ns, *,
and **: P > 0.05, P < 0.05, and P < 0.0501 for indicated comparisons byWilcoxon signed rank tests or Kruskal-Wallis tests followed by Dunn’s post-tests, for
two or multiple comparison groups, respectively. (B) Results of binary logistic regression analyses using NF-κB subunit expression scores as the input
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Although previous reports from various human cancers support a predominantly canonical
NF-κB activation pathway mostly mediated by RelA/P50 [32–37], recent data along with ours
highlight the possibility for a non canonical NF-κB activation pattern in different cancers
[38,39]. In 2005, Lessard and colleagues reported investigations on the expression of multiple
NF-κB subunits in prostate cancer tissue arrays; they found nuclear subunit combinations such
as RelB–P100/P52 and RelA–RelB, introducing for the first time a different NF-κB pattern
associated with the progression of the disease [39]. In addition, a more recent study of head
and neck squamous cell carcinoma proposed a combined effect of both IKKα and IKKβ on the
Fig 5. Immunohistochemical detection of NF-κB in mousemodels of NSCLC.NF-κB subunit expression was assessed by immunohistochemistry in
urethane-induced mouse lung adenomas (A and C) and mutant KRAS-induced lung adenocarcinomas (B and D). (A, B) Representative images. (C, D)
Overall scoring of NF-κB subunit expression levels from four mice per group. Data presented as mean ± SD. ** and ***: P < 0.01, and P < 0.001 for the
indicated color-coded subunit compared with normal bronchial and alveolar epithelium by two-way ANOVA followed by Bonferroni post-tests. Non-significant
comparisons are not indicated.
doi:10.1371/journal.pone.0132527.g005
Fig 6. Schematic illustration of the main findings of the present study.NF-κB subunit expression levels in tumor and stroma cells of 77 patients with
NSCLC are indicated by relative font size. Arrows indicate possible associations of Rel protein expression levels in NSCLC tumor cells with tumor-associated
inflammation and cellular proliferation.
doi:10.1371/journal.pone.0132527.g006
NF-κΒ in NSCLC
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nuclear localization of canonical RelA and alternative RelB and P100/P52 subunits [40]. These
studies, collectively with our results, suggest a possible alternative NF-κB activation pattern in
malignant versus benign cells. This could imply altered intracellular and paracrine signalling
from tumor cells in response to alternative NF-κB activation, since RelA-P50 and RelB–P100/
P52 complexes bind to NF-κB binding sites of different promoters [41]. In addition, several
studies correlate the nuclear membrane transporter chromosomal region maintenance/expor-
tin1 protein (CRM1) with tumor progression in several types of cancers and CRM1 is known
to export RelA from the nucleus into the cytoplasm in ovarian cancer, a phenomenon which
could explain the observed cytoplasmic localization of RelA in the present and other studies
[42–45].
Both RelA and RelB nuclear immunoreactivity have been independently identified in
human NSCLC by two different groups [20, 28]. We report here a possible explanation for the
different results: we identified for the first time that tumor and intratumoral stroma compart-
ments display distinct NF-κB subunit expression patterns, predominantly signified by non-
canonical and canonical subunits, respectively. This contrasting expression pattern could
account for the divergent results, if intratumoral stromal areas were to be interpreted as reflect-
ing tumor areas in terms of NF-κB subunit expression, and warrant careful discrimination of
these distinct areas within each tumor when looking for NF-κB immunoreactivity. Moreover,
we show how this can be readily done using PCNA immunostaining.
A large body of evidence supports that inflammation fuels the progression of bodily tumors,
including lung cancer [46, 47]. In addition to promoting tumor cell proliferation, NF-κB is a
cardinal mediator of innate immune responses in the lungs and other organs, by driving the
expression of several genes involved in cell cycle progression and non-cell-autonomous inflam-
matory signalling [48]. Our findings suggest dual functions for canonical and alternative NF-
κB pathway components in these two processes: RelA expression in tumor areas was elevated
in tumors with higher degrees of inflammation and independently predicted severe tumor-
associated inflammation, while nuclear RelB coincided with proliferating cells within each
tumor. Hence, in NSCLC, RelA may promote the expression of secretory genes encoding
proinflammatory cytokines and chemokines responsible for attracting inflammatory cells to
the tumor site, with possible pro-tumor or anti-tumor functions [48]. In turn, RelB may facili-
tate the expression of cell cycle genes that promote cellular proliferation in a cell-autonomous
fashion.
Studies in animal models are in accord with our findings and consistent with the hypothesis
that non-canonical NF-κB activation pathways are at play in NSCLC. In particular, a previous
study from our group identified that the proteasome (and hence canonical NF-κB pathway)
inhibitor bortezomib dramatically enhanced instead of halting chemical-induced lung carcino-
genesis in mice [49]. Bortezomib has also shown limited efficacy against human NSCLC [50].
Collectively, our data presented here and other reports from the literature indicate that non-
canonical NF-κB transcriptional activity may exist in lung and other tumors.
In addition to triggering tumor-associated inflammation, NF-κΒ is positioned to critically
impact tumor cell proliferation. We found that RelB was expressed in dividing cells of NSCLC,
suggesting that this NF-κΒ subunit may be linked with NSCLC cellular proliferation in an
either positive or negative fashion. Although our study’s design does not allow for the deduc-
tion of functional conclusions on RelB effects on NSCLC cell proliferation, a recent study of
head and neck squamous carcinomas revealed that IKKα, cooperatively with IKKβ, promotes
cellular growth as well as nuclear RelB translocation in this tumor type, suggesting possible
pro-tumor effects for RelB [40]. In addition, Jacque and co-workers showed that RelB exerts
inhibitory effects on tumor cell proliferation by up-regulating tumor protein 53 (TP53) expres-
sion, which are lost upon the occurrence of TP53mutations or loss [51]. We speculate that
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RelB may exert pivotal effects on tumor cell proliferation in our patients with NSCLC, since
many patients with this tumor type have been consistently and repetitively shown to feature all
kinds of TP53 perturbations, including copy number alterations and point mutations, while a
significant proportion retain the wild-type tumor suppressor. In any case, our results collec-
tively with the literature warrant further investigation of RelB functions in cancer.
The limitations of our study are not to be overlooked. First, the descriptive nature of our
findings do not allow for functional implications prior to experimental validation. Second,
since the majority of our study’s participants were male, our conclusions should be regarded as
male-specific. In addition, the limited number of patients with large cell carcinoma does not
allow for conclusions to be drawn for this tumor type.
In summary and despite their inherent limitations, our findings support that alternative
modes of NF-κB activity are functional in human and murine NSCLC, in addition to canonical
NF-κB activity. This non-canonical NF-κB activity may be responsible for the lack of efficacy
of canonical NF-κB inhibitors against NSCLC and warrants further investigation.
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